"Progress is only worthwhile if it is shared by all”
Aristotle
Both Western and Emerging economies face major issues to produce biopharmaceuticals. . The Production volumes and costs of current generation of biopharmaceuticals deprives vast populations around the world access to life-saving medicines.
The acute needs for monoclonal antibodies is also emphasized by the WHO.
World-wide Volume of biopharmaceuticals is limited today to a few % of global pharmaceuticals, despite the fact that targeted therapies are much safer and much more effective.
The Availability of Monoclonal Antibodies, for example, is dramatically lower than needs in Western Countries, particularly in the event of Pandemics and even more so in Emerging Countries where there are almost no Production Units.
The low productivity of current biopharmaceutical production technologies implies enormous investment costs* for low volumes**, resulting in very high treatment costs for the patient.
The Accessibility of these essential
medicines is therefore mainly limited for wealthy people and/or people benefiting from health insurance systems in Western Countries.
We have been working to change the production’s paradigm and we are ready today to propose to countries, governments and main industry’s players our new generation of Biopharmaceutical.
We strongly believe we can make a significant contribution to the world's enormous and urgent unmet needs, including pandemics, while meeting sustainable development goals.
At Biosourcing, we have developed a proprietary technological platform to express proteins of interest in the milk of dedicated animals : We shift from steel bioreactors to natural bioreactors by exploiting state-of-the-art techniques.
Thanks to Unique Expertise in combining Breakthrough technologies: CRISPR-Cas9, the gene-editing technology, the Nuclear Transfer and the reproductive technology, we industrialize the best natural bioreactor of protein : Milk of specialized goat.
In a practical way, we apply gene therapy techniques followed by in vitro fertilization techniques to obtain goats producing in their milk large quantities of biopharmaceuticals such as fully human monoclonal antibodies.
From the milk thus produced in large quantities, pharmaceutical grade purification processes make it possible to obtain high quality biopharmaceuticals at a production cost and carbon footprint drastically lower than current production techniques.
Drastic reduction of capital requirements and production costs, especially for volumes larger than a ton.
Better Biopharmaceuticals (BioBodies) due to improved glycosylation.
High Adaptability and scalability to evolving needs.
Ease of industrialization, reproducibility, and of re-localization of the goat farms.
SDGs:
Good Health and Well Being, Reduction of the carbon footprint, contribution to sustainable development.
We are a team of 15 scientists, with International expertise in their field.
Our laboratories are based in Liège, Belgium, since 2014. Our business model is based on co-development and co-ownership of results, to allow early income and long-term revenues (royalties).
Proposing a sustainable, affordable and accessible alternative to the pharmaceutical production platform of today.
We intent to do so by scaling-up the unprecedented efficiency of its validated BioMilk Platform to produce Biopharmaceuticals.